ARQT · Arcutis Biotherapeutics, Inc.
$26.19
+0.36 (+1.39%)
At close · Aug 14
Market Cap
$3.29B
Shares
125.69M
Arcutis Biotherapeutics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Arcutis Biotherapeutics, Inc. (ARQT) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$725,000
−$107.71M
'22 Q3
22-11-08
·
$2.96M
−$72.02M
'22 Q4
23-02-28
·
$2.78M
−$80.10M
'23 Q1
23-05-09
·
$5.19M
−$70.99M
'23 Q2
23-08-08
▲5156.4%
$38.11M
−$44.77M
'23 Q3
23-11-03
▲356.8%
$13.53M
−$66.28M
'23 Q4
24-02-27
▲1682.4%
$49.57M
−$35.38M
'24 Q1
24-05-14
▲494.6%
$30.86M
−$52.33M
'24 Q2
24-08-14
▲17.4%
$44.76M
−$41.54M
'24 Q3
24-11-06
▲427.6%
$71.36M
−$10.79M
'24 Q4
25-01-13
▲32.8%
$65.85M
−$25.06M
'25 Q1
25-05-06
▲164.1%
$81.50M
−$15.89M
'25 Q2
25-08-06
▲121.7%
$99.22M
$7.41M
'25 Q3
25-10-28
▲81.5%
$129.50M
$17.39M
'25 Q4
26-02-25
▲60.1%
$105.40M
−$11.29M
'26 Q1
26-05-06
LATEST
▲59.3%
$129.86M
$15.01M
'26 Q2
26-08-05
Earnings call
FY26 · Q2
2026-08-05
Arcutis Biotherapeutics, Inc. Q2 2026 Earnings Conference Call
Revenue
$129.86M
▲ 59.3% YoY Diluted EPS
$0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Arcutis Biotherapeutics, Inc. Q1 FY2026 Earnings Call
Confident tone
Atopic dermatitis pediatric sNDA (3 to 24 months)
Pipeline expansion: vitiligo and HS Phase 2 POC
ARQ-234 Phase 1 initiation
Revenue
$105.40M
▲ 60.1% YoY Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-02
TD Cowen 46th Annual Health Care Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-25
Arcutis Biotherapeutics, Inc. Q4 FY2025 Earnings Call
Confident tone
FDA label expansions and submissions
Infant atopic dermatitis (INTEGUMENT trial)
Zareve (topical roflumilast) commercial growth
Revenue
$129.50M*
▲ 81.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-28
Arcutis Biotherapeutics, Inc. Q3 FY2025 Earnings Call
Confident tone
ZORYVE commercial momentum
Pipeline and ARQ-234 biologic
Life cycle management and label expansions
Revenue
$99.22M
▲ 121.7% YoY Diluted EPS
$0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Arcutis Biotherapeutics, Inc. Q2 FY2025 Earnings Call
Confident tone
ZORYVE revenue growth and franchise momentum
Seasonality and quarterly guidance
Conversion from topical steroids
Revenue
$81.50M
▲ 164.1% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Arcutis Biotherapeutics, Inc. Q1 FY2025 Earnings Call
Confident tone
ZORYVE commercial performance and growth
Market expansion from topical steroids
Upcoming regulatory catalysts and label expansion
Revenue
$65.85M
▲ 32.8% YoY Diluted EPS
$-0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Arcutis Biotherapeutics, Inc. Q4 FY2024 Earnings Call
Confident tone
ZORYVE product growth and sales momentum
Foam vs. cream cannibalization concerns
Label expansion and pipeline indications
Revenue
$71.36M*
▲ 427.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Arcutis Biotherapeutics, Inc. Q3 FY2024 Earnings Call
Confident tone
Label expansion and pipeline
Kowa co-promotion partnership
Government payer access (Medicare/Medicaid)
Revenue
$44.76M
▲ 17.4% YoY Diluted EPS
$-0.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Arcutis Biotherapeutics, Inc. Q2 FY2024 Earnings Call
Confident tone
ZORYVE cream (psoriasis) launch
ZORYVE foam (seb derm) launch
Atopic dermatitis launch
Revenue
$30.86M
▲ 494.6% YoY Diluted EPS
$-0.42
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Arcutis Biotherapeutics, Inc. Q1 FY2024 Earnings Call
Confident tone
Atopic dermatitis regulatory and pipeline milestone
ZORYVE cream psoriasis launch momentum
ZORYVE foam seb derm launch
Revenue
$49.57M
▲ 1682.4% YoY Diluted EPS
$-0.32
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Arcutis Biotherapeutics, Inc. Q4 FY2023 Earnings Call
Confident tone
ZORYVE foam seborrheic dermatitis launch
ZORYVE cream psoriasis launch momentum
Payer access and Medicare/Medicaid expansion
Revenue
$13.53M*
▲ 356.8% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-03
Arcutis Biotherapeutics, Inc. Q3 FY2023 Earnings Call
Revenue
$38.11M
▲ 5156.4% YoY Diluted EPS
$-0.73
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Arcutis Biotherapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$5.19M
Diluted EPS
$-1.16
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Arcutis Biotherapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$2.78M
Diluted EPS
$-1.31
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Arcutis Biotherapeutics, Inc. Q4 FY2022 Earnings Call
Revenue
$2.96M*
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Arcutis Biotherapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$725,000
Diluted EPS
$-1.89
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–18 of 18 earnings calls
Key facts
CIK
1787306
CUSIP
03969K108
13F (30d)
269 filings
261 filers
Visit website
Investor relations